Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK14 | O94921 | 6/20 | 0.49 |
| ▸ | CCNY | Q8ND76 | 6/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | CLK1 | P49759 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | ALPG | P10696 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4284373 | 0.84 | CDK14 (0.48) | CDK14CCNYPOLBCLK1TSHR | |
| SCHEMBL4292708 | 0.84 | CDK14 (0.48) | CDK14CCNYPOLBCLK1EPHX2 | |
| SCHEMBL5269902 | 0.84 | CLK1 (0.51) | CDK14CCNYPOLBCLK1TSHR | |
| SCHEMBL4287309 | 0.84 | CDK14 (0.47) | CDK14CCNYPOLBCLK1TSHR | |
| SCHEMBL5266502 | 0.84 | ALDH1A1 (0.56) | CDK14CCNYCLK1ALPLALPI | |
| SCHEMBL4283161 | 0.84 | CDK14 (0.43) | CDK14CCNYMAPK14POLBL3MBTL1 | |
| SCHEMBL4293162 | 0.83 | CDK14 (0.46) | CDK14CCNYPOLBCLK1EPHX2 | |
| SCHEMBL4289521 | 0.83 | CDK14 (0.53) | CDK14CCNYCLK1TSHRALPL | |
| SCHEMBL5271991 | 0.83 | CDK14 (0.55) | CDK14CCNYPOLBCLK1TSHR | |
| SCHEMBL5266768 | 0.82 | CLK1 (0.52) | CDK14CCNYPOLBCLK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1847531-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | GSK3B, GSK3A, GSKIP | CDK14 218/4885CCNY 1293/4885MAPK14 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.